度洛西汀治疗帕金森病疼痛患者疗效及安全性评价

摘要

目的 探讨度洛西汀治疗帕金森病疼痛的临床疗效及安全性. 方法 将30例帕金森患者按照随机数字表法分为两组,每组15例.观察组予以度洛西汀治疗,对照组予以美多巴治疗,观察12周.比较两组患者疼痛缓解状况及不良反应发生率.结果 治疗前两组疼痛评分比较差异无统计学意义(P>0.05);治疗后观察组疼痛评分均较治疗前显著降低(P<0.01),对照组则无显著变化(P>0.05),观察组显著低于对照组(P<0.01).观察组不良反应发生率为6.7%,对照组为33.3%,观察组低于对照组但差异无统计学意义(P>0.05).结论 度洛西汀能显著改善帕金森病患者的疼痛程度,安全性高,优于美多巴治疗.%Objective To explore the efficacy and safety of duloxetine in the treatment of Parkinson's disease (PD) patients with pain.Methods Thirty PD patients were randomly assigned to two groups of 15 ones each.Observation group was treated with duloxetine and control with madopar for 12 weeks.Results There was no significant group difference in pain score before treatment (P>0.05);after treatment pain score lowered more significantly in observation group compared with pretreatment (P<0.01), had no notable changes in the control (P>0.05), and was significantly lower in observation than in control group (P<0.01).The incidence of adverse reactions was respectively 6.7% in observation and 33.3% in control group, the former lower than the latter, but group difference had no statistical significance (P>0.05).Conclusion Duloxetine could notably lessen the pains of PD patients and has higher safety compared with madopar.